Results 211 to 220 of about 8,708 (251)

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa

bioRxiv
Identifying resistance mechanisms to novel antimicrobials informs treatment strategies during infection and antimicrobial development. Studying resistance that develops during the treatment of an infection can provide the most clinically relevant ...
G. Rapsinski, Alecia B. Rokes, D. Van Tyne, V. Cooper   +3 more
semanticscholar   +1 more source

Ceftolozane/tazobactam

Reactions Weekly, 2019
  +5 more sources

Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022–2024: results from the CLEAR registry

Expert Review of Anti-Infective Therapy
Background We report results from the national CLEAR (Canadian Leadership on Antimicrobial Real-Life Usage) registry on the usage of ceftolozane/tazobactam in Canada from 2022 to 2024. Research design and methods The authors reviewed the final data using
G. Zhanel, Rita Dhami, M. Baxter, Maggie Wong, Y. Mirzanejad, J. Kosar, Carlos Cervera, N. Irfan, Sergio Borgia, Alex Serebryanskyy, Robert Ariano, M. Savoie, C. Tascini, A. Walkty, J. Karlowsky   +14 more
semanticscholar   +1 more source

Ceftolozane/tazobactam

Reactions Weekly, 2018
  +4 more sources

Differential frequency of persister cells in clinically derived isolates of Pseudomonas aeruginosa after exposure to cefiderocol and ceftolozane/tazobactam.

Journal of Antimicrobial Chemotherapy
BACKGROUND Bacterial persistence is a phenomenon whereby a subpopulation of bacteria survive high concentrations of an active antibiotic in the absence of phenotypic alterations.
Aliaa Fouad, Samantha E Nicolau, P. Tamma, P. Simner, D. P. Nicolau, C. Gill   +5 more
semanticscholar   +1 more source

Ceftolozane–Tazobactam

Reactions Weekly
Stephanie J. Phelps, Tracy M. Hagemann, Kelley R. Lee   +2 more
  +4 more sources

Ceftolozane-tazobactam versus levofloxacin in urinary tract infection

Lancet, The, 2015
Tom H Boyles
exaly   +4 more sources

Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study

Antimicrobial Agents and Chemotherapy, 2021
Jérôme Lemoine, katy Jeannot, Patrick Plesiat   +2 more
exaly  

Ceftolozane/tazobactam/ganciclovir

Reactions Weekly, 2021
openaire   +1 more source

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa

Clinical Infectious Diseases, 2020
Jason M Pogue, Keith S Kaye, Anthony T Gerlach   +2 more
exaly